{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:23:25Z","timestamp":1793931805184,"version":"4.8.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41409-025-02696-x","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:02:01Z","timestamp":1759312921000},"page":"1565-1573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&amp;G Committee"],"prefix":"10.1038","volume":"60","author":[{"given":"Gandhi","family":"Damaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"de Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Berning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael F.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuella","family":"Guenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojiech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke E.","family":"Karsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie Nguyen","family":"Quoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmina","family":"Serroukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo L.","family":"Ortiz-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"S\u00e1nchez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia J.","family":"Scarisbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"2696_CR1","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/bjd.19644","volume":"184","author":"G Dobos","year":"2021","unstructured":"Dobos G, de Masson A, Ram-Wolff C, Beylot-Barry M, Pham-Ledard A, Ortonne N, et al. Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry. Br J Dermatol. 2021;184:1059\u201367.","journal-title":"Br J Dermatol"},{"key":"2696_CR2","doi-asserted-by":"crossref","unstructured":"Dobos G, Pohrt A, Ram-Wolff C, Lebb\u00e9 C, Bouaziz JD, Battistella M, et al. Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients. Cancers. 2020;12:2921.","DOI":"10.3390\/cancers12102921"},{"key":"2696_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703\u201314.","journal-title":"Blood"},{"key":"2696_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.17258","volume":"181","author":"JJ Scarisbrick","year":"2019","unstructured":"Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019;181:350\u20137.","journal-title":"Br J Dermatol"},{"key":"2696_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jaad.2014.10.006","volume":"72","author":"MA Marchetti","year":"2015","unstructured":"Marchetti MA, Pulitzer MP, Myskowski PL, Dusza SW, Lunning MA, Horwitz SM, et al. Cutaneous manifestations of human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia\/lymphoma: a single-center, retrospective study. J Am Acad Dermatol. 2015;72:293\u2013301.","journal-title":"J Am Acad Dermatol"},{"key":"2696_CR6","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","volume":"30","author":"R Dummer","year":"2012","unstructured":"Dummer R, Quaglino P, Becker JC, Hasan B, Karrasch M, Whittaker S, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012;30:4091\u20137.","journal-title":"J Clin Oncol"},{"key":"2696_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/annonc\/mdt480","volume":"25","author":"DJ Straus","year":"2014","unstructured":"Straus DJ, Duvic M, Horwitz SM, Hymes K, Goy A, Hernandez-Ilizaliturri FJ, et al. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Ann Oncol. 2014;25:206\u201310.","journal-title":"Ann Oncol"},{"key":"2696_CR8","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/cncr.21449","volume":"104","author":"E Marchi","year":"2005","unstructured":"Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer. 2005;104:2437\u201341.","journal-title":"Cancer"},{"key":"2696_CR9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00277-014-2121-1","volume":"93","author":"C Pellegrini","year":"2014","unstructured":"Pellegrini C, Stefoni V, Casadei B, Maglie R, Argnani L, Zinzani PL. Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. Ann Hematol. 2014;93:1853\u20137.","journal-title":"Ann Hematol"},{"key":"2696_CR10","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"YH Kim","year":"2018","unstructured":"Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1192\u2013204.","journal-title":"Lancet Oncol"},{"key":"2696_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390:555\u201366.","journal-title":"Lancet"},{"key":"2696_CR12","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","volume":"33","author":"JJ Scarisbrick","year":"2015","unstructured":"Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33:3766\u201373.","journal-title":"J Clin Oncol"},{"key":"2696_CR13","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/bjd.18541","volume":"182","author":"S Ritchie","year":"2020","unstructured":"Ritchie S, Qureshi I, Molloy K, Yoo J, Shah F, Stevens A, et al. Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T-cell lymphoma at a tertiary care centre: should we avoid chemotherapy in conditioning regimes? Br J Dermatol. 2020;182:807\u20139.","journal-title":"Br J Dermatol"},{"key":"2696_CR14","doi-asserted-by":"crossref","unstructured":"de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, et al. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023;401:1941\u201350.","DOI":"10.1016\/j.ejca.2023.113038"},{"key":"2696_CR15","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s41409-020-01197-3","volume":"56","author":"E Domingo-Domenech","year":"2021","unstructured":"Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and S\u00e9zary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2021;56:1391\u2013401.","journal-title":"Bone Marrow Transplant"},{"key":"2696_CR16","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","volume":"28","author":"RF Duarte","year":"2010","unstructured":"Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:4492\u20139.","journal-title":"J Clin Oncol"},{"key":"2696_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbmt.2019.08.019","volume":"26","author":"M Iqbal","year":"2020","unstructured":"Iqbal M, Reljic T, Ayala E, Sher T, Murthy H, Roy V, et al. Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2020;26:76\u201382.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2696_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14737140.2024.2305356","volume":"24","author":"A Goyal","year":"2024","unstructured":"Goyal A, Foss F. Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma. Expert Rev Anticancer Ther. 2024;24:41\u201358.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2696_CR19","doi-asserted-by":"publisher","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","volume":"195","author":"J Latzka","year":"2023","unstructured":"Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2023. Eur J Cancer. 2023;195:113343.","journal-title":"Eur J Cancer"},{"key":"2696_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jtct.2024.08.020","volume":"30","author":"A Goyal","year":"2024","unstructured":"Goyal A, O'leary D, Dabaja B, Weng WK, Zain J, Cutler C, et al. ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and S\u00e9zary syndrome. Transplant Cell Ther. 2024;30:1047\u201360.","journal-title":"Transplant Cell Ther"},{"key":"2696_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41409-023-01958-w","volume":"58","author":"I Yakoub-Agha","year":"2023","unstructured":"Yakoub-Agha I, Greco R, Onida F, de la C\u00e1mara R, Ciceri F, Corbacioglu S, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transplant. 2023;58:696\u2013700.","journal-title":"Bone Marrow Transplant"},{"key":"2696_CR22","doi-asserted-by":"crossref","unstructured":"Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022;140:419\u201337.","DOI":"10.1182\/blood.2021012057"},{"key":"2696_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","volume":"72","author":"RT Hoppe","year":"2015","unstructured":"Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72:286\u201392.","journal-title":"J Am Acad Dermatol"},{"key":"2696_CR24","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"SJ Whittaker","year":"2010","unstructured":"Whittaker SJ, Demierre M-F, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485\u201391.","journal-title":"J Clin Oncol"},{"key":"2696_CR25","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","volume":"32","author":"RF Duarte","year":"2014","unstructured":"Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a European Society for Blood and Marrow Transplantation Lymphoma Working Party extended analysis. J Clin Oncol. 2014;32:3347\u20138.","journal-title":"J Clin Oncol"},{"key":"2696_CR26","doi-asserted-by":"publisher","first-page":"102679","DOI":"10.1016\/j.eclinm.2024.102679","volume":"73","author":"A Bozonnat","year":"2024","unstructured":"Bozonnat A, Beylot-Barry M, Dereure O, D'Incan M, Quereux G, Guenova E, et al. Real-life efficacy of immunotherapy for S\u00e9zary syndrome: a multicenter observational cohort study. EClinicalMedicine. 2024;73:102679.","journal-title":"EClinicalMedicine"},{"key":"2696_CR27","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s12185-024-03753-9","volume":"119","author":"MJ Lechowicz","year":"2024","unstructured":"Lechowicz MJ, Smith C, Ristuccia R, Dwyer K. Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis. Int J Hematol. 2024;119:736\u201344.","journal-title":"Int J Hematol"},{"key":"2696_CR28","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","volume":"34","author":"S Fuji","year":"2016","unstructured":"Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34:3426\u201333.","journal-title":"J Clin Oncol"},{"key":"2696_CR29","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713\u201322.","journal-title":"Blood"},{"key":"2696_CR30","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","volume":"28","author":"NS Agar","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730\u20139.","journal-title":"J Clin Oncol"},{"key":"2696_CR31","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/PAT.0000000000000166","volume":"46","author":"M Pulitzer","year":"2014","unstructured":"Pulitzer M, Myskowski PL, Horwitz SM, Querfeld C, Connolly B, Li J, et al. Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors. Pathology. 2014;46:610\u20136.","journal-title":"Pathology"},{"key":"2696_CR32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jaad.2013.09.007","volume":"70","author":"ME Kadin","year":"2014","unstructured":"Kadin ME, Hughey LC, Wood GS. Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2014;70:374\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"2696_CR33","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.clml.2017.11.004","volume":"18","author":"BM Cyrenne","year":"2018","unstructured":"Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, et al. Transplantation in the treatment of primary cutaneous aggressive epidermotropic cytotoxic CD8-positive T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18:e85\u201393.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2696_CR34","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1080\/10428194.2020.1790555","volume":"61","author":"I Isufi","year":"2020","unstructured":"Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, et al. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leuk Lymphoma. 2020;61:2955\u201361.","journal-title":"Leuk Lymphoma"},{"key":"2696_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2340\/00015555-2950","volume":"98","author":"M-C Br\u00fcggen","year":"2018","unstructured":"Br\u00fcggen M-C, Kerl K, Haralambieva E, Schanz U, Chang YT, Ignatova D, et al. Aggressive rare T-cell lymphomas with manifestation in the skin: a monocentric cross-sectional case study. Acta Derm Venereol. 2018;98:835\u201341.","journal-title":"Acta Derm Venereol"},{"key":"2696_CR36","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1182\/bloodadvances.2020001627","volume":"4","author":"W-K Weng","year":"2020","unstructured":"Weng W-K, Arai S, Rezvani A, Johnston L, Lowsky R, Miklos D, et al. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Adv. 2020;4:4474\u201382.","journal-title":"Blood Adv"},{"key":"2696_CR37","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s41409-024-02236-z","volume":"59","author":"SL Morris","year":"2024","unstructured":"Morris SL, Thomas BR, Palanicawandar R, Whittaker S, Child F, Wain M, et al. Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2024;59:874\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"2696_CR38","doi-asserted-by":"publisher","first-page":"214ra171","DOI":"10.1126\/scitranslmed.3007420","volume":"5","author":"W-K Weng","year":"2013","unstructured":"Weng W-K, Armstrong R, Arai S, Desmarais C, Hoppe R, Kim YH. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Sci Transl Med. 2013;5:214ra171.","journal-title":"Sci Transl Med"},{"key":"2696_CR39","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/bjd.18806","volume":"182","author":"R Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 R, Ram-Wolff C, Battistella M, Peffault de Latour R, Petit A, Bouaziz JD, et al. Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides. Br J Dermatol. 2020;182:1503\u20134.","journal-title":"Br J Dermatol"},{"key":"2696_CR40","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/bjd.18215","volume":"181","author":"M Dumont","year":"2019","unstructured":"Dumont M, Ram-Wolff C, Roelens M, Brice P, Peffault de Latour R, Battistella M, et al. Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas. Br J Dermatol. 2019;181:1315\u20137.","journal-title":"Br J Dermatol"},{"key":"2696_CR41","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/bjd.19220","volume":"183","author":"A Dangien","year":"2020","unstructured":"Dangien A, Ram-Wolff C, Brice P, Battistella M, Roelens M, Moins-Teisserenc H, et al. Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas. Br J Dermatol. 2020;183:961\u20132.","journal-title":"Br J Dermatol"},{"key":"2696_CR42","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","volume":"28","author":"M Duvic","year":"2010","unstructured":"Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010;28:2365\u201372.","journal-title":"J Clin Oncol"},{"key":"2696_CR43","first-page":"03581","volume":"S0360-3016","author":"K Elsayad","year":"2024","unstructured":"Elsayad K, Guenova E, Fournier B, Fernandes C, Clementel E, Papadavid E, et al. Real-world pattern-of-care analysis of primary cutaneous lymphomas radiation therapy among European organisation for research and treatment of cancer members. Int J Radiat Oncol Biol Phys. 2024;S0360-3016:03581\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2696_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/10428194.2019.1658106","volume":"61","author":"MK Baron","year":"2020","unstructured":"Baron MK, Osborn JD, Tao R, Lee CJ. Haploidentical hematopoietic cell transplantation for mycosis fungoides\/Sezary syndrome. Leuk Lymphoma. 2020;61:231\u20133.","journal-title":"Leuk Lymphoma"},{"key":"2696_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41409-023-02122-0","volume":"59","author":"A Goyal","year":"2024","unstructured":"Goyal A, O\u2019Leary D, Foss F. Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis. Bone Marrow Transplant. 2024;59:41\u201351.","journal-title":"Bone Marrow Transplant"},{"key":"2696_CR46","unstructured":"Onida F, Cavallaro F, Alberti-Violetti S, Goldaniga M, Barbullushi K, Serpenti F, et al. Allogeneic hematopoietic cell transplantation in patients with advanced mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis including 63 consecutive patients with long-term median follow-up. Bone Marrow Transplant 2024;59:20\u2013139; 103-O112."},{"key":"2696_CR47","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","volume":"6","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv. 2022;6:920\u201330.","journal-title":"Blood Adv"},{"key":"2696_CR48","doi-asserted-by":"publisher","first-page":"184.e1","DOI":"10.1016\/j.jtct.2022.11.028","volume":"29","author":"A Mussetti","year":"2023","unstructured":"Mussetti A, Kanate AS, Wang T, He M, Hamadani M, Finel SR, et al. Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas. Transplant Cell Ther. 2023;29:184.e1\u2013e9.","journal-title":"Transplant Cell Ther"},{"key":"2696_CR49","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.bbmt.2018.06.026","volume":"24","author":"F Ayuk","year":"2018","unstructured":"Ayuk F, Beelen DW, Bornh\u00e4user M, Stelljes M, Zabelina T, Finke J, et al. Relative impact of HLA matching and non-HLA donor characteristics on outcomes of allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018;24:2558\u201367.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2696_CR50","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.1200\/JCO.2006.08.0952","volume":"24","author":"I Yakoub-Agha","year":"2006","unstructured":"Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10\/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24:5695\u2013702.","journal-title":"J Clin Oncol"},{"key":"2696_CR51","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/JCO.19.02408","volume":"38","author":"G Fatobene","year":"2020","unstructured":"Fatobene G, Rocha V, St Martin A, Hamadani M, Robinson S, Bashey A, et al. Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: from the LWP-EBMT, Eurocord, and CIBMTR. J Clin Oncol. 2020;38:1518\u201326.","journal-title":"J Clin Oncol"},{"key":"2696_CR52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2991\/chi.k.210529.001","volume":"3","author":"M Stamouli","year":"2021","unstructured":"Stamouli M, Gkirkas K, Karagiannidi A, Iliakis T, Chondropoulos S, Thomopoulos T, et al. Allogeneic stem cell transplantation with a novel reduced intensity conditioning regimen for the treatment of patients with primary cutaneous T-cell lymphomas. Clin Hematol Int. 2021;3:72\u20136.","journal-title":"Clin Hematol Int"},{"key":"2696_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ajh.27531","volume":"100","author":"T Luft","year":"2025","unstructured":"Luft T, Gras L, Koster L, Kr\u00f6ger N, Schr\u00f6der T, Platzbecker U, et al. Methotrexate versus mycophenolate mofetil prophylaxis in allogeneic hematopoietic cell transplantation for chronic myeloid malignancies: a retrospective analysis on Behalf of the Chronic Malignancies Working Party of the EBMT. Am J Hematol. 2025;100:38\u201351.","journal-title":"Am J Hematol"},{"key":"2696_CR54","doi-asserted-by":"publisher","first-page":"963689724127040","DOI":"10.1177\/09636897241270401","volume":"33","author":"Z Gu","year":"2024","unstructured":"Gu Z, Li F, Li M, Zhang L, Xu S, Wang L, et al. Similar survival but less chronic GVHD in antithymocyte globulin-based myeloablative haploidentical transplant compared with matched sibling transplant for adult T-cell acute lymphoblastic leukemia\/lymphoma. Cell Transplant. 2024;33:9636897241270401.","journal-title":"Cell Transplant"},{"key":"2696_CR55","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1080\/10428194.2024.2376164","volume":"65","author":"ER Gordon","year":"2024","unstructured":"Gordon ER, Trager MH, Kwinta BD, Stonesifer CJ, Lee KJ, Adeuyan O, et al. Maintenance therapy for CTCL: importance for prevention of disease progression. Leuk Lymphoma. 2024;65:1883\u201390.","journal-title":"Leuk Lymphoma"},{"key":"2696_CR56","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/s41409-018-0400-5","volume":"54","author":"M Yoshimitsu","year":"2019","unstructured":"Yoshimitsu M, Utsunomiya A, Fuji S, Fujiwara H, Fukuda T, Ogawa H, et al. A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma. Bone Marrow Transplant. 2019;54:1266\u201374.","journal-title":"Bone Marrow Transplant"},{"key":"2696_CR57","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7:e157\u201367.","journal-title":"Lancet Haematol"},{"key":"2696_CR58","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1111\/jdv.15661","volume":"33","author":"A Pileri","year":"2019","unstructured":"Pileri A, Fava P, Fuligni F, Gunnella S, Guglielmo A, Astrua C, et al. Bexarotene as maintenance treatment after therapies other than skin-directed therapy in advanced-stage mycosis fungoides: a pilot study. J Eur Acad Dermatol Venereol. 2019;33:e367\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2696_CR59","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.clml.2020.06.020","volume":"20","author":"MR Kudelka","year":"2020","unstructured":"Kudelka MR, Switchenko JM, Lechowicz MJ, Esiashvili N, Flowers CR, Khan MK, et al. Maintenance therapy for cutaneous T-cell lymphoma after total skin electron irradiation: evidence for improved overall survival with ultraviolet therapy. Clin Lymphoma Myeloma Leuk. 2020;20:757\u201367.e3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2696_CR60","first-page":"00508","volume":"S1470-2045","author":"SP Iyer","year":"2024","unstructured":"Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, et al. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Lancet Oncol. 2024;S1470-2045:00508\u20134.","journal-title":"Lancet Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02696-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02696-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02696-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:04:30Z","timestamp":1781539470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02696-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2696"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02696-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GD: Honoraria: Takeda, Amgen. Travel support: Takeda. Research Support: Takeda, Ideogen. ADM: Honoraria: Takeda, Kyowa Kirin, Helsinn, Recordati Rare Diseases, Almirall, Novartis. Travel support: Kyowa Kirin, Recordati Rare Diseases, Novartis. Research Support: Kyowa Kirin. PD: none reported. AB: Honoraria: Takeda, Amgen, Janssen, Roche, Maat Pharma Research Support: Takeda, Roche, Novartis, Janssen. PB: none reported. SF: none reported. RFD: none reported. CPF: Consultancy: AbbVie, Arvinas, Atarabio, BMS, GenMab, Gilead\/Kite, Incyte, Lilly, Morphosys, Ono, Roche, SERB, SOBI, Takeda. Research funding: BeiGene, AbbVie\/GenMab, Incyte. EG: honoraria and\/or grant support from Mallinckrodt, Helsinn, Takeda Pharmaceuticals, Recordati Rare Diseases, Novartis, Sanofi, Stemline Therapeutics, and Kyowa Kirin. OH: Research fund, BMS, Bluueprint, Abbvie, Roche. CK: Research support BMS, Travel support Takeda. AT: Honoraria: Genesis Pharma, SOBI, Johnson & Johnson, Abbvie. OT: Honoraria: Takeda, BeiGene. Travel support: Takeda, Abbvie, Astra-Zeneca, BeiGene. Research Support: Takeda. WJ: Honoraria: Takeda, AbbVie. IEK: is supported by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)\u2014493624047 (Clinician Scientist CareerS Muenster), Honoraria: Kite\/Gilead, Travel grants: BeiGene. SNQ: Honoraria: Jazz Pharma, Novartis, Abbvie, Gilead; Travel support: Abbvie, Gilead, Sanofi, Neovii. YS: none reported. GW: Honoraria: Takeda, Gilead Scienes, Novartis, Clinigen; Travel support: Medac, Janssen. AS: Honoraria: Takeda, BMS\/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, GenMab, Abbvie, Jazz Pharmaceuticals, Therakos, Menarini; Consultancy: Takeda, BMS\/Celgene, Novartis, Janssen, Gilead, Sanofi, GenMab, Abbvie; Speaker\u2019s Bureau: Takeda; Research Support: Takeda; Non-profit organizations: Presidency of the EBMT. EP: Takeda, Recordati, Helsinn, Kyowa Kirin, Novartis, UCB, Leo, Abbvie, Jansen. PLOR: Honoraria: Takeda, Kyowa Kirin, Helsinn, Recordati Rare Diseases. Travel support: UCB, Kyowa Kirin, Recordati Rare Diseases, Novartis. ALR: none reported. ISO: none reported. JS: Honoraria & Consultancy Helsinn, Recordati, Takeda, Therakos, Kyowa Kirin. IYA: Honoraria: Novartis, BMS, Kite\/Gilead, Janssen and Pfizer. FO: Honoraria: Takeda, MEDAC Pharma, Kyowa Kirin; Travel support: Takeda, Jazz Pharma, Kyowa Kirin; NS: Travel support: Beigene, Roche, Stocks: BMS.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}